Induction Therapy With Docetaxel, Cisplatin, 5-Fluoro Uracil and Pembrolizumab in Untreated Locally-advanced Unresectable Squamous Cell Head and Neck Carcinoma (Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma. PICH Study)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Fluorouracil (Primary) ; Pembrolizumab (Primary) ; Carboplatin
- Indications Head and neck cancer
- Focus Therapeutic Use
- Acronyms PICH Study
- 18 Jan 2018 Planned End Date changed from 1 Dec 2021 to 1 Mar 2020.
- 18 Jan 2018 Planned primary completion date changed from 1 Dec 2019 to 1 Mar 2020.
- 18 Jan 2018 Planned initiation date changed from 1 Dec 2017 to 1 Mar 2018.